Appointments Manchester: 01625581781 Appointments London: 02070094400

Ongoing Patient Studies

Professor Stanga regularly has patient studies ongoing at the London Vision Clinic. If this is something you would like to be considered for please get in touch with us on 020 7009 4400.

Please note that we have set up several Clinical Interventional Studies in Dry Early, Intermediate and Late Stage Age-related Macular Degeneration, and not all of them require surgery.

DRY AMD is the most common cause of severe loss of central vision and for which there is currently no treatment and carries a significant cost to society.

All our current studies are industry-sponsored and therefore are at no cost to patients. Patients are also be reimbursed for travel expenses (if enrolled, and up to a limit per visit). All our studies already have all necessary Ethics Committee approvals.

Our current Clinical Studies in Dry Early, Intermediate and Late Stage Age-related Macular Degeneration are as follows:

  • Photo-Biomodulation light-therapy in Early/Intermediate AMD. This is a non-invasive treatment using specific wavelengths of light to stimulate cellular function in the retina. The aim of the treatment is to arrest the progression of the disease at its earliest stage and whilst vision is still good.
  • We are part of ongoing research into the effectiveness of PBM, but the treatment is already certified for use in the EU and previous studies have shown no safety concerns or significant side effects.
Inclusion criteriaExclusion criteria
1. ≥ 50 years of age

2. Snellen Visual Acuity: 6/30 to 6/7.5

3. Dry AMD with Drusen

History of Wet AMD and Intraocular Injections

 

  • Anti-Complement Intravitreal Injections in Advanced Dry AMD/Geographic Atrophy
Inclusion criteriaExclusion criteria
1. ≥ 60 years of age

2. Snellen Visual Acuity: 6/95 or better

3. Geographic Atrophy secondary to AMD

 

History of Wet AMD and Intraocular Injections

 

  • Gene Therapy Surgery in Advanced Dry AMD/Geographic Atrophy
Inclusion criteriaExclusion criteria
1. ≥18 years of age

2. Snellen Visual Acuity: 6/60 or better

3. Geographic Atrophy secondary to AMD

History of Wet AMD and Intraocular Injections

 
Please do contact us if interested in participating in any of our current Clinical Interventional Studies in Dry Early, Intermediate and Late Stage Age-related Macular Degeneration.

Those patients who are not keen in participating in studies will be able to access the Photo-Biomodulation light-therapy on a self-paying basis.